These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36191643)

  • 1. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
    Epperson CN; Rubinow DR; Meltzer-Brody S; Deligiannidis KM; Riesenberg R; Krystal AD; Bankole K; Huang MY; Li H; Brown C; Kanes SJ; Lasser R
    J Affect Disord; 2023 Jan; 320():353-359. PubMed ID: 36191643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
    Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
    J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
    Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
    CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexanolone in Postpartum Depression:
    Gerbasi ME; Meltzer-Brody S; Acaster S; Fridman M; Bonthapally V; Hodgkins P; Kanes SJ; Eldar-Lissai A
    J Womens Health (Larchmt); 2021 Mar; 30(3):385-392. PubMed ID: 33181049
    [No Abstract]   [Full Text] [Related]  

  • 7. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
    Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S
    Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL; Lipschitz A; Pitts CD; Davies JT
    Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
    Zheng W; Cai DB; Zheng W; Sim K; Ungvari GS; Peng XJ; Ning YP; Wang G; Xiang YT
    Psychiatry Res; 2019 Sep; 279():83-89. PubMed ID: 31323375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
    Leader LD; O'Connell M; VandenBerg A
    Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between commonly used patient-reported outcome tools in postpartum depression clinical practice and the Hamilton Rating Scale for Depression.
    Gerbasi ME; Eldar-Lissai A; Acaster S; Fridman M; Bonthapally V; Hodgkins P; Kanes SJ; Meltzer-Brody S
    Arch Womens Ment Health; 2020 Oct; 23(5):727-735. PubMed ID: 32666402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
    Sheehan DV; Rozova A; Gossen ER; Gibertini M
    Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving clinical response in postpartum depression leads to improvement in health-related quality of life.
    Gerbasi ME; Kosinski M; Meltzer-Brody S; Acaster S; Fridman M; Huang MY; Bonthapally V; Hodgkins P; Kanes SJ; Eldar-Lissai A
    Curr Med Res Opin; 2021 Jul; 37(7):1221-1231. PubMed ID: 33719782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
    Zou J; Yang L; Yang G; Gao J
    Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M; McIntyre RS; Szamosi J; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.